Literature DB >> 8228333

Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D.

D D Bikle1, E Gee, S Pillai.   

Abstract

1,25(OH)2D has numerous actions on many tissues. Analogs of 1,25(OH)2D are being sought that are selective, to further an understanding of the mechanisms of action of 1,25(OH)2D and to improve its therapeutic efficacy. Toward these ends we examined eight analogs of 1,25(OH)2D for their ability to regulate 25OHD metabolism by keratinocytes. Choosing the three most potent, we then examined their ability to inhibit keratinocyte proliferation, stimulate cornified envelope formation (a marker of differentiation), and bind to the 1,25(OH)2D receptor (VDR). 1,25(OH)2-24F2-D, 1,25(OH)2-delta 16-D, and 1,25(OH)2-delta 16,23yne-D proved the most potent in inhibiting 1,25(OH)2D production and stimulating 24,25(OH)2D production, being approximately 10-100 times more potent than 1,25(OH)2D itself. 1,25(OH)2-delta 16-D had the highest affinity for the VDR (fourfold higher than that for 1,25(OH)2D itself) and had the greatest ability both to inhibit proliferation and to stimulate differentiation. 1,25(OH)2-delta 16,23yne-D also had a higher affinity for the VDR but was of less or equal potency in stimulating cornified envelope formation and inhibiting proliferation. 1,25(OH)2-24F2-D, which was the most potent regulator of 25OHD metabolism, had a lower affinity for the VDR and was less potent than 1,25(OH)2D in inhibiting proliferation. Our results indicate that even in the same cell different analogs have different rank orders of potency for the various actions of 1,25(OH)2D.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228333     DOI: 10.1111/1523-1747.ep12371681

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Pilot study on the bioactivity of vitamin d in the skin after oral supplementation.

Authors:  Clara Curiel-Lewandrowski; Jean Y Tang; Janine G Einspahr; Yira Bermudez; Chiu Hsieh Hsu; Melika Rezaee; Alex H Lee; Joseph Tangrea; Howard L Parnes; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-02

2.  Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways.

Authors:  P L Chang; T F Lee; K Garretson; C W Prince
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

Review 3.  Role of the calcium-sensing receptor in calcium regulation of epidermal differentiation and function.

Authors:  Chia-Ling Tu; Daniel D Bikle
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 4.690

Review 4.  Vitamin D in cutaneous carcinogenesis: part II.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

5.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

6.  A Sleeping Beauty DNA transposon-based genetic sensor for functional screening of vitamin D3 analogues.

Authors:  Nicklas H Staunstrup; Nynne Sharma; Rasmus O Bak; Lars Svensson; Thomas K Petersen; Lene Aarenstrup; Karsten Kristiansen; Lars Bolund; Jacob Giehm Mikkelsen
Journal:  BMC Biotechnol       Date:  2011-04-07       Impact factor: 2.563

7.  Assessment of Vitamin D Level in Patients with Psoriasis and Its Correlation with Disease Severity: A Case-Control Study.

Authors:  Ranju Pokharel; Sudha Agrawal; Prajwal Pandey; Madhab Lamsal
Journal:  Psoriasis (Auckl)       Date:  2022-09-13

8.  Low vitamin D-modulated calcium-regulating proteins in psoriasis vulgaris plaques: S100A7 overexpression depends on joint involvement.

Authors:  Susana Cubillos; Johannes Norgauer
Journal:  Int J Mol Med       Date:  2016-08-26       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.